SCHEMBL22473535

SCHEMBL22473535

Cn1nccc1[C@@H]1CCCN1C(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.41
WDR77 Q9BQA1 1/20 0.41
CHRNB2 P17787 4/20 0.35
CHRNA4 P43681 4/20 0.35
CHRNA7 P36544 3/20 0.35
CHRNB4 P30926 3/20 0.35
CHRNA3 P32297 3/20 0.35
ALDH1A1 P00352 2/20 0.35
CHRNA2 Q15822 2/20 0.35
LMNA P02545 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
HTR3E A5X5Y0 1/20 0.35
PSIP1 O75475 1/20 0.35
TRPA1 O75762 1/20 0.35
HTR3B O95264 1/20 0.35
CHRNA1 P02708 1/20 0.35
CHRNG P07510 1/20 0.35
MAPT P10636 1/20 0.35
CHRNB1 P11230 1/20 0.35
CYP2A6 P11509 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22473543 1.00 PRMT5 (0.41) PRMT5WDR77CHRNB2CHRNA4CHRNA7
SCHEMBL22473351 0.95 PRMT5 (0.45) PRMT5WDR77CHRNB2CHRNA4CHRNA7
SCHEMBL22473182 0.95 PRMT5 (0.45) PRMT5WDR77CHRNB2CHRNA4CHRNA7
SCHEMBL24737113 0.80 GAA (0.50) CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3
SCHEMBL22473156 0.77 SCN9A (0.42) PRMT5WDR77HCAR2
SCHEMBL22473295 0.77 SCN9A (0.42) PRMT5WDR77HCAR2
SCHEMBL22473217 0.76 PRMT5 (0.33) PRMT5WDR77
SCHEMBL22473378 0.74 SCD (0.32) PRMT5WDR77
SCHEMBL23493159 0.74 PRMT5 (0.45) PRMT5WDR77CHRNB2CHRNA4CHRNA7
SCHEMBL28887472 0.73 PRMT5 (0.52) PRMT5WDR77CHRNB2CHRNA4CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210171516-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2021-06-10 US disclosed
US-10787446-B2 Therapeutic compounds and methods of use thereof GENENTECH, INC. (US) 2020-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10787446-B2 Therapeutic compounds and methods of use thereof AVPR1B, C3AR1, RHEB PRMT5 92/4885WDR77 589/4885CHRNB2 1972/4885
US-20210171516-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF AVPR1B, C3AR1, RHEB PRMT5 92/4885WDR77 589/4885CHRNB2 1972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.